{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:23:16Z","timestamp":1784013796809,"version":"3.55.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T00:00:00Z","timestamp":1470700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAPES (Ministry of Education, Brazil)"},{"name":"CnPQ"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0159924","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T17:41:10Z","timestamp":1470764470000},"page":"e0159924","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4326-0024","authenticated-orcid":false,"given":"Dimas Alexandre","family":"Kliemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane Valle","family":"Tovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Gorini da Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Luiz","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02893380","article-title":"Viral hepatitis: new data on hepatitis C infection","volume":"9","author":"E Szabo","year":"2003","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"K Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"ref3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2334-12-S2-S2","article-title":"Chronic HCV infection: epidemiological and clinical relevance","volume":"12","author":"S Zaltron","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/erv.11.55","article-title":"Vaccination for hepatitis C virus: closing in on an evasive target","volume":"10","author":"J Halliday","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"e1002656","DOI":"10.1371\/journal.ppat.1002656","article-title":"A new evolutionary model for hepatitis C virus chronic infection","volume":"8","author":"RR Gray","year":"2012","journal-title":"PLoS Pathog"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1053\/j.gastro.2007.03.116","article-title":"The hepatitis C virus life cycle as a target for new antiviral therapies","volume":"132","author":"JM Pawlotsky","year":"2007","journal-title":"Gastroenterology"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jac\/dkr215","article-title":"Directly acting antivirals against hepatitis C virus","volume":"66","author":"V Soriano","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"E Poveda","year":"2014","journal-title":"Antiviral Res"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"C Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkp388","article-title":"Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)","volume":"65","author":"TL Kieffer","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment","volume":"26","author":"J Vermehren","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/jvh.12051","article-title":"The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank","volume":"20","author":"R Alves","year":"2013","journal-title":"J Viral Hepat"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"F McPhee","year":"2013","journal-title":"Hepatology"},{"key":"ref14","article-title":"Development of sofosbuvir for the treatment of hepatitis C virus infection","author":"E Lawitz","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Y Suzuki","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","article-title":"Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b","volume":"54","author":"F Suzuki","year":"2012","journal-title":"J Clin Virol"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1","volume":"373","author":"DL Wyles","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"DR Nelson","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/01.qai.0000209899.05126.e4","article-title":"The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes","volume":"41","author":"DA van de Vijver","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molcel.2016.01.024","article-title":"The Coding Region of the HCV Genome Contains a Network of Regulatory RNA Structures","volume":"62","author":"N Pirakitikulr","year":"2016","journal-title":"Mol Cell"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"F McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.coviro.2012.08.004","article-title":"The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance","volume":"2","author":"M Gotte","year":"2012","journal-title":"Curr Opin Virol"},{"issue":"51","key":"ref23","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"MH Powdrill","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/jvh.12405","article-title":"Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy","volume":"22","author":"C Hedskog","year":"2015","journal-title":"J Viral Hepat"},{"key":"ref25","article-title":"Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study","author":"DM Jensen","year":"2015","journal-title":"Liver Int"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/00822942-200403040-00005","article-title":"HCVDB: hepatitis C virus sequences database","volume":"3","author":"C Combet","year":"2004","journal-title":"Appl Bioinformatics"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/molbev\/mst197","article-title":"MEGA6: Molecular Evolutionary Genetics Analysis version 6.0","volume":"30","author":"K Tamura","year":"2013","journal-title":"Mol Biol Evol"},{"issue":"6 Pt B","key":"ref28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3851\/IMP2426","article-title":"Antiviral resistance and direct-acting antiviral agents for HCV","volume":"17","author":"AL Aloia","year":"2012","journal-title":"Antivir Ther"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"e39652","DOI":"10.1371\/journal.pone.0039652","article-title":"HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"V Cento","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.dld.2011.07.002","article-title":"Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development","volume":"43","author":"V Svicher","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"O Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DA DeGoey","year":"2014","journal-title":"J Med Chem"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","article-title":"Virologic response and characterisation of HCV genotype 2\u20136 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"O Lenz","year":"2013","journal-title":"J Hepatol"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"T Pilot-Matias","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor","volume":"59","author":"W Kati","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350901400108","article-title":"Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes","volume":"14","author":"AI Maiga","year":"2009","journal-title":"Antivir Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2014.02.011","article-title":"Antiviral therapy of hepatitis C in 2014: do we need resistance testing?","volume":"105","author":"MD Schneider","year":"2014","journal-title":"Antiviral Res"},{"issue":"Suppl 1","key":"ref38","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"C Sarrazin","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"F Poordad","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.02386-13","article-title":"Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors","volume":"58","author":"VC Di Maio","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/AAC.00444-08","article-title":"Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479","volume":"52","author":"S Ali","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"49","key":"ref42","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro","volume":"278","author":"G Migliaccio","year":"2003","journal-title":"J Biol Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0159924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T15:06:15Z","timestamp":1657033575000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0159924"}},"subtitle":[],"editor":[{"given":"Ravi","family":"Jhaveri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0159924","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}